TY - JOUR

T1 - Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors

AU - Hansen, Morten

AU - Juul Hare, Kristine

AU - Holst, Jens Juul

AU - Knop, Filip Krag

PY - 2011/6

Y1 - 2011/6

N2 - Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.

AB - Incretin-based treatments have emerged as new modalities for the treatment of type 2 diabetes mellitus (T2DM). In contrast to currentantidiabetic treatments, these agents target both insulin insufficiency and inappropriate hyperglucagonemia*two major components of type2 diabetic pathophysiology*both known to contribute significantly to the hyperglycemic state of patients with T2DM. This article outlines therole of hyperglucagonemia in type 2 diabetic pathophysiology, summarizes the physiologic effects of glucagon-like peptide-1 (GLP-1), andgives an introduction to incretin-based treatments with emphasis on their glucagon-lowering effects. Finally, we review available glucagondata from current clinical studies on incretin-based treatment modalities (dipeptidyl peptidase 4 [DPP4] inhibitors and GLP-1 receptoragonists). Most of these studies suggest that both DPP4 inhibitors and GLP-1 receptor agonists lower fasting and postprandial plasmaglucagon, and recent data suggest that these effects contribute importantly to the glucose-lowering effect of these treatments.

M3 - Journal article

VL - 2

SP - 7

EP - 13

JO - Journal of Clinical Metabolism & Diabetes

JF - Journal of Clinical Metabolism & Diabetes

SN - 2041-8019

IS - 2

ER -